Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market Size to Grow by USD 1.79 billion, AbbVie Inc. and Bayer AG Among Key Vendors - Technavio

Corporate Breaking News

Home : Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market Size to Grow by USD 1.79 billion, AbbVie Inc. and Bayer AG Among Key Vendors - Technavio

Jul 25 2022	Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market Size to Grow by USD 1.79 billion, AbbVie Inc. and Bayer AG Among Key Vendors - Technavio
NEW YORK, July 25, 2022 /PRNewswire/ -- DLBCL is a cancer of B-lymphocytes and is the most common type of Non-Hodgkins Lymphoma (NHL) among adults. It is a fast-growing and complex form of NHL and is difficult to treat. NHL refers to a group of cancers of the lymphatic system that...


Source:https://www.prnewswire.com:443/news-releases/diffuse-large-b-cell-lymphoma-dlbcl-therapeutics-market-size-to-grow-by-usd-1-79-billion-abbvie-inc-and-bayer-ag-among-key-vendors---technavio-301591925.html

Related News
» Ozonetel Commended by Frost & Sullivan for Its Highly Differentiated Cloud-based Contact Center Solutions with Trendsetting, Cost-effective Features » Almirall achieves Core Net Sales growth of 5.1% to 436.6 MM Euros in H1